Evaxion Biotech A/S — Form 6-K Summary
Business context and reporting period
Evaxion Biotech A/S, a Danish foreign private issuer, filed this Form 6-K on February 7, 2024, covering February 2024. The filing reports amendments to the company’s Articles of Association following the closing of a public offering.
Capitalization and key financial matters
- The company completed a public offering of 3,750,000 American Depositary Shares (ADSs), or pre-funded warrants in lieu of ADSs, together with warrants to purchase up to 3,750,000 ADSs.
- The combined public offering price was $4.00 per ADS, or per ADS underlying a pre-funded warrant, plus the accompanying warrant.
- The filing does not provide a clear value for gross proceeds, net proceeds, cash balance, revenue, profit, cash flow, margins, debt, or liquidity.
- The company registered an aggregate increase of nominal share capital of DKK 7,575,000 for 7,575,000 shares issued in connection with the offering. Total nominal share capital increased to DKK 48,115,546.
- A further nominal share capital increase of DKK 1,975,000 was registered on February 5, 2024, following the exercise of pre-funded warrants for 1,975,000 ordinary shares. Total nominal share capital increased to DKK 50,090,546.
Material changes and potential dilution
- Following the offering and warrant exercise, the company had 7,575,000 newly issued shares and 1,975,000 shares issued upon pre-funded warrant exercise.
- Remaining pre-funded warrants provide rights to subscribe for 2,795,000 ADSs at an exercise price of $1.4537 per warrant ADS.
- The amended Articles of Association provide for 39,375,000 warrants. Series A Warrants have a five-year term and a $4.00 exercise price; Placement Agent Warrants have a five-year term and a $5.40 exercise price.
- Nominal DKK 20,325,000 of shares is reserved for issuance upon exercise of pre-funded warrants.
- The authorization under Article 2.10 to grant warrants, including pre-funded warrants to investors, lenders, consultants, or advisers, fully lapsed after the offering.
Guidance, outlook, risks, and unusual items
The filing contains no financial guidance or operating outlook. The principal investor considerations are the substantial increase in shares and outstanding warrant instruments, potential future dilution from warrant exercises, and the absence of financial-condition or liquidity information in this filing.
Facts investors should verify
- Gross and net cash proceeds from the public offering and their intended use.
- The company’s fully diluted share count, including all remaining pre-funded warrants and the 39,375,000 warrants.
- Exercise terms, expiration dates, and potential anti-dilution provisions applicable to each warrant class.
- Updated cash runway, operating cash requirements, debt obligations, and financing needs in the company’s latest Form 20-F or subsequent filings.
- The attached amended Articles of Association, identified as Exhibit 1.1.